AVI BioPharma - News Release: "AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced data presentations for eteplirsen (the non-proprietary name assigned to AVI-4658), the Company's investigational exon skipping therapy for the treatment of Duchenne muscular dystrophy, at the 16th International Congress of the World Muscle Society taking place Oct. 18-22, 2011 in Almancil, Algarve, Portugal."
'via Blog this'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment